Abstracts tagged "interstitial lung disease"

Abstract Number: 0950 • ACR Convergence 2024
Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde (MAA) Modified Vimentin Induces Fibrotic Lung Changes
Wenxian Zhou¹, Michael Duryee², Nozima Aripova², Jill Poole², Carlos Hunter², Amy Nelson², Bryant England², Ted Mikuls² and Geoffrey Thiele², ¹University of Nebraska Medical Center, Bellevue, NE, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is the most overrepresented cause of death among RA patients, yet the mechanisms underlying lung fibrosis remain…
Abstract Number: 1163 • ACR Convergence 2024
Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population
Aurélie Mourot¹, Beatrice Panuta¹, Juliette Charbonneau¹, Ange Mounkam Ngeuleu¹, Caroline Vo², Eric Rich³, Josiane Bourré-Tessier³, Edith Villeneuve³, Hélène Manganas³, Andréanne Gauthier³, Julie Morisset³, Sabrina Anh-Tu Hoa³ and Océane Landon-Cardinal³, ¹University of Montreal, Montreal, QC, Canada, ²Hôpital Charles Lemoyne, Montreal, QC, Canada, ³Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada
Background/Purpose: Antisynthetase syndrome (ASSD) is characterized by interstitial lung disease (ILD), myositis, polyarthritis, Raynaud’s phenomenon, dermatomyositis-like rash and mechanic’s hands. ILD may present with isolated…
Abstract Number: 1689 • ACR Convergence 2024
Pulmonary Function Test Reference Equations May Drive Inequitable Classification of Restrictive Lung Disease Severity in Systemic Sclerosis
Kamini Kuchinad¹, Rachel Wallwork², Matthew Lammi³, Christopher Mecoli¹, Julie Paik¹, Fredrick Wigley⁴, Robert Wise¹, Laura Hummers⁵, Ami Shah⁶ and Ji Soo Kim¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Towson, MD, ³Johns Hopkins University Division of Pulmonary and Critical Care Medicine, Baltimore, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ⁵Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁶Division of Rheumatology, Johns Hopkins University, Ellicott City, MD
Background/Purpose: Black individuals with systemic sclerosis (SSc) have an increased frequency and severity of interstitial lung disease (ILD) as compared to their White counterparts. Pulmonary…
Abstract Number: 2075 • ACR Convergence 2024
A Retrospective Cohort Study Assessing Outcomes and Safety in Patients Receiving Low Dose vs High Dose Cyclophosphamide in Myositis Interstitial Lung Disease (ILD)
Saadia Sasha Ali¹, Alexandra Lawrence², Katie Bechman³, Amit Patel⁴, Surinder biring³, Sophia Steer⁴, Arti Mahto⁵, Catherine Myall⁴, Louise Pollard⁶, Marium Naqvi⁴, Amelia Holloway⁴, Rosaria Salerno⁴, Flora Dell'accio⁴, Sangita Agarwal⁷, Boris Lams⁸, Alex West⁷ and Patrick Gordon⁹, ¹King's College Hospital, Epsom, United Kingdom, ²Guys and St Thomas's Hospital, London, United Kingdom, ³King's College London, London, United Kingdom, ⁴King's College Hospital, London, United Kingdom, ⁵King's College Hospital, London, United Kingdom, ⁶University Hospital Lewisham, London, United Kingdom, ⁷Guy's and St Thomas' Hopsital, London, United Kingdom, ⁸Guys and St Thomas' Hospital, London, ⁹nhs, London, United Kingdom
Background/Purpose: ILD is associated with poor survival in patients with idiopathic inflammatory myopathies (IIM). Cyclophosphamide is often used in the management of myositis associated ILD…
Abstract Number: 2466 • ACR Convergence 2024
Ranked Composite Important Difference (RCID) Scores in Patients with Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease
Francesco Del Galdo¹, Lesley-Anne Bissell², Rozeta Simonovska³ and Margarida Alves⁴, ¹University of Leeds, Leeds, United Kingdom, ²Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁴Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany
Background/Purpose: The ACR Composite Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) was developed to measure the probability of improvement in response to treatment in…
Abstract Number: 0333 • ACR Convergence 2024
Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease
shiri keret¹, Raisa Silva², Irada Choudhuri², Eugenia Gkiaouraki³, Tanya Chandra⁴, Nantakarn Pongtarakulpanit⁵, shreya Sriram³, silvia Martinez Laverde³, Dana Ascherman³, Siamak Mogahadam⁵, Chester Oddis⁵ and Rohit Aggarwal⁶, ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Lung involvement is the most common and severe extra-muscular manifestation of Idiopathic Inflammatory Myopathies (IIM). Early identification of patients at risk for lung transplant…
Abstract Number: 0690 • ACR Convergence 2024
Can Immunosuppression or Vasodilation Prevent the Onset of Interstitial Lung Disease in Systemic Sclerosis? An Association Analysis from the EUSTAR Database
Liubov Petelytska¹, Lorenzo Tofani², Elise Siegert³, Elisabetta Zanatta⁴, Gianluca Moroncini⁵, Christina Bergmann⁶, vanessa smith⁷, Gabriela Riemekasten⁸, Kamal Solanki⁹, Fabio Cacciapaglia¹⁰, Britta Maurer¹¹, José da Silva¹², Marija Geroldinger-Simić¹³, Ana Rodrigues¹⁴, Madelon Vonk¹⁵, Jeska de Vries-Bouwstra¹⁶, Anna-Maria Hoffmann-Vold¹⁷, Oliver Distler¹⁸ and Cosimo Bruni¹⁹, and on behalf of the EUSTAR collaborators, ¹Bogomolets National Medical University, Kyiv, Kyyiv, Ukraine, ²University of Florence, Florence, Italy, ³Charité University Hospital, Berlin, Germany, ⁴Unit of Rheumatology, Padova University, Padova, Italy, ⁵Marche Polytechnic University, Ancona, Italy, ⁶Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, ⁷Ghent University Hospital, Gent, Belgium, ⁸University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ⁹Waikato Hospital, Hamilton, New Zealand, ¹⁰Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ¹¹University Hospital Bern, University Bern, Bern, Switzerland, ¹²University of Coimbra, Coimbra, Portugal, ¹³Johannes Kepler University, Linz, Austria, ¹⁴Hospital Curry Cabral-Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal, ¹⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁶Leiden University Medical Center, Leiden, Netherlands, ¹⁷Oslo University Hospital, Oslo, Norway, ¹⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ¹⁹University of Zurich, Zurich, Switzerland
Background/Purpose: Inflammation and vasculopathy may play a role in the development of interstitial lung disease (ILD) in systemic sclerosis (SSc). Pre-clinical evidence showed possible preventive…
Abstract Number: 0952 • ACR Convergence 2024
Single Cell RNA-seq of Scleroderma-associated Interstitial Lung Disease Lung Explants Reveals an Active, Cytotoxic Natural Killer Cell Population
Cristina Padilla, Eleanor Valenzi, Tracy Tabib, Banafsheh Nazari, Patrizia Fuschiotti and Robert Lafyatis, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Scleroderma-associated interstitial lung disease (SSc-ILD) is the leading cause of death among SSc patients. Loss of alveolar epithelial cells (AEC) and bronchial cell hyperplasia,…
Abstract Number: 1168 • ACR Convergence 2024
Improved Survival in Patients with Myositis-Associated Interstitial Lung Disease (ILD) During the Period 2011 to 2023: Comparative and Integrative Analysis of Three Multicenter Cohorts in Japan
Masataka Kuwana¹, Kenichi Masui², Atsushi Kawakami³, Takafumi Suda⁴, Shinji Sato⁵, Yasushi Kawaguchi⁶, Takeshi Johkoh⁷, Tomoaki Hoshino⁸, Naoki Shimada⁹, Yasuhiro Kondoh¹⁰, Yoshinori Tanino¹¹, Tohru Takeuchi¹², Yoshiyuki Abe¹³, Naoki Kimura¹⁴, Yasushi Inoue¹⁵, Keisuke Tomii¹⁶, Toru Arai¹⁷, Kunihiro Yamaoka¹⁸, Kaneshige Sasaki¹⁹, Taio Naniwa²⁰, Ran Nakashima²¹, Kenjiro Shima²², Osamu Nishiyama²³, Yuko Waseda²⁴, Hiroshi Mukae²⁵, Hirofumi Chiba²⁶, Keigo Ikeda²⁷, Kazuya Ichikado²⁸, Yohei Kirino², Koichi Amano²⁹, Takashi Nawata³⁰, Tomoo Kishaba³¹, Daisuke Asatori³², Daisuke Kobayashi²² and Takahisa Gono³³, ¹Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ²Yokohama City University School of Medicine, Yokohama, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴Hamamatsu University School of Medicine, Hamamatsu, Japan, ⁵Tokai University School of Medicine, Isehara, Japan, ⁶Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁷Kansai Rosai Hospital, Amagasaki, Japan, ⁸Kurume University School of Medicine, Kurume, Japan, ⁹International University of Health and Welfare, Ohtawara, Japan, ¹⁰Tosei General Hospital, Seto, Japan, ¹¹Fukushima Medical University School of Medicine, Fukushima, Japan, ¹²Osaka Medical and Pharmaceutical University, Takatsuki, Japan, ¹³Juntendo University School of Medicine, Tokyo, Japan, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan, ¹⁶Kobe City Medical Center General Hospital, Kobe, Japan, ¹⁷NHO Kinki Chuo Chest Medical Center, Sakai, Japan, ¹⁸Kitasato University School of Medicine, Sagamihara, Japan, ¹⁹Kainan Hospital, Yatomi, Japan, ²⁰Nagoya City University, Nagoya, Japan, ²¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²²Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²³Kindai University Faculty of Medicine, Osakasayama, Japan, ²⁴University of Fukui, Eiheiji, Japan, ²⁵Nagasaki University Hospital, Nagasaki, Japan, ²⁶Sapporo Medical University, Sapporo, Japan, ²⁷Juntendo University Urayasu Hospital, Urayasu, Japan, ²⁸Saiseikai Kumamoto Hospital, Kumamoto, Japan, ²⁹Saitama Medical Centre, Saitama Medical University, Kawagoe, Japan, ³⁰Yamaguchi University Graduate School of Medicine, Ube, Japan, ³¹Okinawa Chubu Hospital, Uruma, Japan, ³²Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, ³³Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: ILD is the leading cause of mortality in patients with idiopathic inflammatory myopathies, and rapidly progressive ILD, associated mainly with anti-MDA5 antibody, is the…
Abstract Number: 1690 • ACR Convergence 2024
FAPI-PET/CT as a Predictor of Accelerated Lung Function Deterioration in Systemic Sclerosis Related Interstitial Lung Disease (ILD): Preliminary-interim Analysis from a Confirmatory Risk Factor Study
Armin Atzinger¹, Yixing Huang², Koray Tascilar³, Nadine Bayerl⁴, Jörg Distler⁵, Katrin Staudt³, Havanur Kartalczik⁶, Cosimo Bruni⁷, Oliver Distler⁸, Anna-Maria Hoffmann-Vold⁹, Tobias Bäuerle⁴, Andrea Prenner¹⁰, Florian Putz², Katharina Breininger¹¹, Torsten Kuwert¹², Bernhard Kainz¹¹, Georg Schett¹³ and Christina Bergmann¹⁴, ¹Department of Nuclear Medicine, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department Radiation Therapy, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department Radiology, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Erlangen, Germany, ⁵Universitätsklinikum Düsseldorf and Heinrich-Heine-Universität Düsseldorf, Duesseldorf, Germany, ⁶Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Frankfurt, Germany, ⁷University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ¹⁰Department Artificial Intelligence in Biomedical Engineering; FAU, Erlangen, Germany, ¹¹Department Artificial Intelligence in Biomedical Engineering, Erlangen, Germany, ¹²Department Nuclear Medicine, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Erlangen, Germany, ¹³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ¹⁴Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany
Background/Purpose: 68Ga-FAPI-PET/CT is a novel imaging method monitoring in-vivo fibroblast activation. We recently described an association of 68Ga-FAPI-uptake with deterioration of Forced Vital capacity (FVC)…
Abstract Number: 2084 • ACR Convergence 2024
Efficacy and Safety of a Step-down Regimen of Low Dosage of Glucocorticoids Combined with Early Administration of Synthetic or Biologic Immunosuppressants in Anti-synthetase Syndrome: A Pilot Study
Edoardo Conticini¹, Paolo Cameli¹, Silvia Grazzini¹, Miriana d'Alessandro¹, Laura Bergantini¹, Brunetta Porcelli¹, Maria Antonietta Mazzei¹, Luca Cantarini¹, Elena Bargagli¹ and Bruno Frediani², ¹Università di Siena, Siena, Italy, ²Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
Background/Purpose: Anti-synthetase syndrome (ASS) is a rare autoimmune disease characterized by the presence of anti-aminoacyl-transfer-RNA synthetase antibodies (ARS) and the involvement of muscles, skin, joints,…
Abstract Number: 2470 • ACR Convergence 2024
Progression Patterns in Systemic Sclerosis – Associated Interstitial Lung Diseases
anais Roeser¹, Pierre-Yves Brillet¹, Marouane Boubaya¹, Frédéric Caux¹, Robin Dhote¹, Hilario Nunes¹ and Yurdagül Uzunhan², ¹APHP, Bobigny, France, ²Service de Pneumologie, Hôpital Avicenne, AP-HP, Bobigny, France
Background/Purpose: The occurrence of interstitial lung disease (ILD) in the course of systemic sclerosis (SSc) is associated with increased morbidity and mortality. SSc-ILD evolution is…
Abstract Number: 0338 • ACR Convergence 2024
Anti-MDA5 Antibody-positive Dermatomyositis Associated Interstitial Lung Disease – Survival Benefit of Treatment with Rituximab, Janus Kinase Inhibitor and Glucocorticoid Combination in a Prospective Cohort
Cheryl Chun Man Ng¹, Kitty Yan Kwok¹, Chup-Hei Ho¹, Tze-Chung Ho¹, Chu-Oi Ciang² and Moon-Ho Leung¹, ¹Queen Elizabeth Hospital, Hong Kong, Hong Kong, ²QEH, Hong Kong., Hong Kong, China
Background/Purpose: Anti-melanoma differentiation-associated protein 5 antibody associated dermatomyositis (Anti-MDA5 DM) is known to be an aggressive disease. Earlier cohorts reported a 1-year mortality of 38%-57%, with rapidly…
Abstract Number: 0691 • ACR Convergence 2024
Predictors of Response and Long-term Efficacy and Safety of Nintedanib in Systemic Sclerosis-Interstitial Lung Disease: Data from an Italian Multicentre Study
Corrado Campochiaro¹, Giacomo De Luca², Maria-Grazia Lazzaroni³, Giuseppe Armentaro⁴, Amelia Spinella⁵, Chiara Bellocchi⁶, Barbara Ruaro⁷, Anna Stanziola⁸, Devis Benfaremo⁹, Enrico De Lorenzis¹⁰, Beatrice Moccaldi¹¹, Francesco Bonomi¹², Lorenzo Bianchessi¹³, Florenzo Iannone¹⁴, Fabio Cacciapaglia¹⁵, Lorenzo Beretta¹⁶, Serena Guiducci¹⁷, Veronica Codullo¹⁸, Silvia Laura Bosello¹⁹, Giovanna Cuomo²⁰, Elisabetta Zanatta¹¹, Nicoletta Del Papa⁴, Paolo Airò³, paola Confalonieri⁷, Gianluca Moroncini⁹, Dilia Giuggioli⁵, Lorenzo Dagna²¹ and Marco Matucci-Cerinic²², ¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ²Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ³Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ⁴Scleroderma Clinic, Dip. Reumatologia, ASST G. Pini-CTO, Milan, Italy, ⁵Scleroderma Unit, University of Modena and Reggio Emilia, Modena, Italy, ⁶Università degli Studi di Milano, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, ⁷Unit of Respiratory Medicine, University of Trieste, Trieste, Italy, ⁸Unit of Respiratory Medicine, Federico II University Hospital, Napoli, Italy, ⁹Department of Clinical and Molecular Sciences, Marche Polytechnic University & Department of Internal Medicine, Marche University Hospital, Ancona, Italy, ¹⁰Catholic University of the Sacred Heart, Roma, Rome, Italy, ¹¹Unit of Rheumatology, Padova University, Padova, Italy, ¹²Azienda Ospedaliera Universitaria Careggi, Florence, Florence, Italy, ¹³Unit of Rheumatology, San Matteo Hospital, Pavia, ¹⁴Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ¹⁵Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ¹⁶Scleroderma Unit, Fondazione IRCCS Ca' Granda, University of Milan, Milan, Italy, ¹⁷Division of Rheumatology, Scleroderma Unit, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹⁸Unit of Rheumatology, San Matteo Hospital, Pavia, Italy, ¹⁹Unit of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²⁰Università degli studi della Campania Luigi Vanvitelli, Napoli, Italy, ²¹IRCCS San Raffaele Scientific Institute, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milano, Italy, Milan, Italy, ²²University San Raffaele Milano, Milano, Milan, Italy
Background/Purpose: The SENSCIS trial and the SENSCIS-ON study have shown that nintedanib (NTD) reduces the rate of decline in Interstitial Lung Disease (ILD) in Systemic…
Abstract Number: 0955 • ACR Convergence 2024
Inhibition of Interleukin-2-Inducible T Cell Kinase with Soquelitinib Demonstrates Efficacy in Preventing Lung Damage in Murine Models of Systemic Sclerosis
Goncalo Boleto¹, Anne Cauvet², James Rose³, Lih-Yun Hsu³, Richard A. Miller³ and Yannick Allanore⁴, ¹Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal., Lisbon, Portugal, ²Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ³Corvus Pharmaceuticals, 863 Mitten Road, Burlingame, Burlingame, CA, ⁴Université Paris Cité, Paris, France
Background/Purpose: T cells abnormal activation plays a pivotal role in the early inflammatory stages of systemic sclerosis (SSc). Compelling evidence supports that SSc has a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].